TherapeuticsMD (NASDAQ:TXMD) Announces Quarterly Earnings Results

TherapeuticsMD (NASDAQ:TXMD) issued its quarterly earnings results on Tuesday. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($6.12) by $6.13, FiscalAI reports. TherapeuticsMD had a net margin of 5.34% and a return on equity of 0.32%. The company had revenue of $0.87 million during the quarter, compared to analysts’ expectations of $19.77 million.

TherapeuticsMD Price Performance

NASDAQ:TXMD opened at $2.07 on Wednesday. TherapeuticsMD has a 12-month low of $0.99 and a 12-month high of $2.95. The firm has a market capitalization of $23.95 million, a price-to-earnings ratio of 34.50 and a beta of 0.61. The stock’s 50 day moving average price is $2.04 and its two-hundred day moving average price is $2.14.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently raised its position in TherapeuticsMD stock. Citadel Advisors LLC boosted its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,273 shares of the company’s stock after purchasing an additional 19,073 shares during the quarter. Citadel Advisors LLC owned about 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent reporting period. 30.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of TherapeuticsMD in a research report on Thursday, July 2nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, TherapeuticsMD has an average rating of “Sell”.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.